Figure 5

G-CSF/anti-G-CSF mAb-mediated expansion of CD11b⁺Gr-1⁺myeloid cells during myelosuppression does not impair antigen-specific CD8⁺T cell proliferative responses. (A) B6 mice (n = 4/group) were treated with 4 mg cyclophosphamide (CTX) on day -1 and adoptively transferred with 10⁶ pmel-1 CD8⁺ T cells on day 0. On days 1 and 10, mice received a prime boost vaccination s.c. with gp100_25-33 peptide (100 μg, i.v.) concomitant with poly I:C (200 μg, i.p.). On day 0, day 2, and day 4, mice were treated i.p. with G-CSF/anti-G-CSF mAb complexes (1 μg G-CSF plus 5 μg anti-G-CSF mAb), G-CSF alone (1 μg G-CSF), or vehicle alone (n = 4/group). (B) Peripheral blood was harvested at the timepoints indicated and the percentage of donor pmel-1 CD8⁺ T cells among lymphocytes was assessed by flow cytometry. (C) The percentage of myeloid cells (CD11b⁺Gr-1⁺) among peripheral blood was assessed at day 9. All data are representative of 2 independent experiments.